Tom Powles: Renal cancer highlights at ASCO24 – KIM1 biomarker data stands out
Toni Choueiri shared a post by Tom Powles, Director of Barts Cancer Center, on X and added:
“3 biomarker presentations in kidney cancer from 2 mRCC trials (CLEAR/KYN426) with Brian Rini, Robert Motzer and an adjuvant trial with KIM-1 by Laurence Albiges.
Discussion by Wenxin Xu from Dana-Farber Lank Center for Genitourinary Oncology.
Vincent is a rising star in biomarkers and first to report on KIM1 in RCC–Don’t miss his talk!”
Quoting Tom Powles‘ post:
“Renal cancer highlights at ASCO24.
KIM1 biomarker data (blood) stands out. KIM1 (TIM1-4 family) increases in kidney injury and is immune suppressive (Treg). Already used for nephrotoxicity.
Robert Motzer presented compelling data from adjuvant ipilimumab/nivolumab at AACR24. A second positive study would be meaningful?”
Source: Toni Choueiri/X and Tom Powles/X
Toni Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Kohlberg Chair and Professor of Medicine at Harvard Medical School. He is the Medical Director of International Strategic Initiatives at Dana-Farber and past President of the Medical Staff at DFCI (2016-2018).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023